BRITISH BIOMEDICAL FIRM, VIRACORP, PARTNERS WITH INCEPTA TO DEVELOP INNOVATIVE NASAL COVID-19 VACCINE

ViraCorp has joined forces with leading pharmaceutical company, Incepta, to develop a unique, needle-free COVID-19 vaccine, which uses state-of-the-art intra-nasal technology.

Under its subsidiary ViraVac, ViraCorp’s new vaccine is based on the work of Lancaster virologist Dr Muhammad Munir, who has taken on the role of Chief Scientific Officer at ViraCorp. It features a unique formulation and delivery method which means it not only protects against COVID-19, but it can be delivered by nasal spray and transported using traditional cold transportation. This has numerous advantages compared to other vaccines currently on the market.

“Having a vaccination which can be transported easily and administered through a nasal delivery system reduces the heavy infrastructure and training requirements of a vaccination drive and will help ensure the vaccine can reach some of the world’s most remote communities,” said Dr Munir.

In collaboration with ViraCorp, Incepta is committed to providing next-generation vaccines. Incepta’s facility has a yearly production capacity of 180 million single doses, or 1 billion doses in multi-dose format. “Incepta always explores to acquire, develop and optimise new vaccine processes as well as production technologies. This collaboration will be a milestone to provide a new delivery system making it a very attractive solution for vaccination in developing countries like ours, alongside remote communities,” said Dr Abdul Muktadir, Chairman and Managing Director, Incepta Vaccine Ltd.

Jon Chadwick, CEO of ViraCorp, is confident about where this and other recently announced partnerships will lead. “By combining our resources, we will ensure the highest standard of quality in our work to make vaccines more available, both logistically and financially,” Jon said.

Dr Munir added: “This partnership with Incepta is a critical milestone to further develop our next generation COVID-19 vaccine which offers protections and blocks transmission independent of the nature of SARS-COV-2 variants”.

“The intranasal vaccine has been extensively validated in pre-clinical studies and has the safety profile of several decades”, added Senior Research Associate Dr Mohammed Rohaim in Dr Munir’s team.
---

ViraCorp is a British biomedical firm that is on a mission to improve the health outcomes for as many of the world’s population as possible. ViraCorp and its subsidiaries are aiming to lead the fight against viral infections and diseases, while also providing humanitarian aid to the people and places that need it most.

Incepta Vaccine Ltd. was established in 2011 with the primary objective to provide high quality vaccines to the vast majority of the population in Bangladesh and across the globe at an affordable price. It is the first human vaccine manufacturing company in Bangladesh with a state-of-art facility that is fully compliant with the WHO GMP requirements. Incepta is committed to improving its capacity through building genuine and equitable partnerships with researchers and relevant development agencies worldwide.